# Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma

> **NCT06653517** · PHASE2 · RECRUITING · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 12 (estimated)

## Conditions studied

- Ameloblastoma
- BRAF V600E Mutation Positive

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT06653517
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06653517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06653517, "Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06653517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*